{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T07:29:17Z","timestamp":1784964557752,"version":"3.55.0"},"reference-count":176,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"TrePsy project from the European Union\u2019s Horizon Europe","award":["101079256"],"award-info":[{"award-number":["101079256"]}]},{"name":"The National Science Centre, Poland","award":["2021\/43\/B\/NZ7\/01162"],"award-info":[{"award-number":["2021\/43\/B\/NZ7\/01162"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Cannabidiol (CBD) is one of the most studied compounds of Cannabis sativa and has attracted significant interest due to its therapeutic and beneficial properties, which have been confirmed in numerous preclinical and clinical studies over the last few years. A great advantage of CBD over the other widely known Cannabis sativa ingredient, \u0394-9-tetrahydrocannabinol (THC), is that CBD does not exert intoxicating and psychoactive effects, making it an attractive candidate for therapeutic applications in neurological disorders. CBD has been shown to exert antioxidant, analgesic, anti-inflammatory, and neuroprotective effects, with therapeutic potential for various neurological conditions. To date, the only drug that consists solely of highly purified CBD is Epidiolex, which is used in the management of severe forms of epilepsy such as Dravet syndrome and Lennox\u2013Gastaut syndrome. Another legal medication containing CBD (albeit with the addition of THC) is Sativex, used to alleviate spasticity in multiple sclerosis. Besides epilepsy, preclinical data suggest that CBD alone may be potentially beneficial in treating chronic pain, multiple sclerosis, Alzheimer\u2019s and Parkinson\u2019s diseases, or stroke. The safety profile of CBD is generally considered favorable, as the most commonly reported adverse effects are mild (e.g., somnolence, diarrhea). However, much attention should be paid as CBD-driven drug\u2013drug interactions have been reported. This review article aims to assess the outcomes of preclinical and clinical research on CBD\u2019s effects in various neurological conditions while also addressing potential risks and concerns related to its use.<\/jats:p>","DOI":"10.3390\/ph19020330","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T13:15:35Z","timestamp":1771334135000},"page":"330","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cannabidiol in Neurology: Current Insights and Translational Perspectives"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1440-1932","authenticated-orcid":false,"given":"Magdalena","family":"Bia\u0142o\u0144","sequence":"first","affiliation":[{"name":"Department of Neurochemistry, Maj Institute of Pharmacology, Polish Academy of Sciences, 31-343 Cracow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6980-8273","authenticated-orcid":false,"given":"Marta","family":"K\u0119dziora","sequence":"additional","affiliation":[{"name":"Department of Neurochemistry, Maj Institute of Pharmacology, Polish Academy of Sciences, 31-343 Cracow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0091-0066","authenticated-orcid":false,"given":"Katarzyna","family":"Starowicz","sequence":"additional","affiliation":[{"name":"Department of Neurochemistry, Maj Institute of Pharmacology, Polish Academy of Sciences, 31-343 Cracow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"228","DOI":"10.5534\/wjmh.230352","article-title":"Cannabidiol alleviates chronic prostatitis and chronic pelvic pain syndrome via CB2 receptor activation and TRPV1 desensitization","volume":"43","author":"Piao","year":"2025","journal-title":"World J. Mens Health"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.pbb.2019.05.002","article-title":"Cannabidiol (CBD) reduces anxiety-related behavior in mice via an FMRP-independent mechanism","volume":"181","author":"Zieba","year":"2019","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Chesworth, R., Cheng, D., Staub, C., and Karl, T. (2022). Effect of long-term cannabidiol on learning and anxiety in a female Alzheimer\u2019s disease mouse model. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.931384"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1007\/s11064-024-04102-2","article-title":"Cannabidiol exerts sedative and hypnotic effects in normal and insomnia model mice through activation of 5-HT1A receptor","volume":"49","author":"Liu","year":"2024","journal-title":"Neurochem. Res."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Sorkhou, M., Bedder, R.H., and George, T.P. (2021). The behavioral sequelae of cannabis use in healthy people: A systematic review. Front. Psychiatry, 12.","DOI":"10.3389\/fpsyt.2021.630247"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"C\u00e1sedas, G., de Yarza-Sancho, M., and L\u00f3pez, V. (2024). Cannabidiol (CBD): A systematic review of clinical and preclinical evidence in the treatment of pain. Pharmaceuticals, 17.","DOI":"10.3390\/ph17111438"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"173879","DOI":"10.1016\/j.pbb.2024.173879","article-title":"Cannabidiol attenuates prepulse inhibition disruption by facilitating TRPV1 and 5-HT1A receptor-mediated neurotransmission","volume":"245","author":"Pedrazzi","year":"2024","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"111029","DOI":"10.1016\/j.pnpbp.2024.111029","article-title":"New insights into the involvement of serotonin and BDNF-TrkB signalling in cannabidiol\u2019s antidepressant effect","volume":"133","author":"Guldager","year":"2024","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"107623","DOI":"10.1016\/j.pharmthera.2020.107623","article-title":"FK506 binding proteins and inflammation related signalling pathways; basic biology, current status and future prospects for pharmacological intervention","volume":"215","author":"Annett","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"6983","DOI":"10.1093\/nar\/gkv615","article-title":"FKBP51 employs both scaffold and isomerase functions to promote NF-\u03baB activation in melanoma","volume":"43","author":"Romano","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.bbi.2023.05.008","article-title":"Cannabidiol alleviates neuroinflammation and attenuates neuropathic pain via targeting FKBP5","volume":"111","author":"Wang","year":"2023","journal-title":"Brain Behav. Immun."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s43556-023-00156-w","article-title":"Structure, function and drug discovery of GPCR signaling","volume":"4","author":"Cheng","year":"2023","journal-title":"Mol. Biomed."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s40263-020-00741-5","article-title":"Critical aspects affecting cannabidiol oral bioavailability and metabolic elimination, and related clinical implications","volume":"34","author":"Perucca","year":"2020","journal-title":"CNS Drugs"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Hossain, K.R., Alghalayini, A., and Valenzuela, S.M. (2023). Current challenges and opportunities for improved cannabidiol solubility. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241914514"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Millar, S.A., Stone, N.L., Yates, A.S., and O\u2019Sullivan, S.E. (2018). A systematic review on the pharmacokinetics of cannabidiol in humans. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.01365"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1038\/s41598-025-87621-4","article-title":"A high-fat meal significantly impacts the bioavailability and biphasic absorption of cannabidiol (CBD) from a CBD-rich extract in men and women","volume":"15","author":"Saals","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1124\/dmd.120.000350","article-title":"Cytochrome P450\u2013catalyzed metabolism of cannabidiol to the active metabolite 7-hydroxy-cannabidiol","volume":"49","author":"Beers","year":"2021","journal-title":"Drug Metab. Dispos."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.2174\/1570159X21666230322143401","article-title":"Update on cannabidiol clinical toxicity and adverse effects: A systematic review","volume":"21","author":"Madeo","year":"2023","journal-title":"Curr. Neuropharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/s41386-020-0667-2","article-title":"Adverse effects of cannabidiol: A systematic review and meta-analysis of randomized clinical trials","volume":"45","author":"Chesney","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"974","DOI":"10.2174\/1570159X17666190603171901","article-title":"Cannabidiol adverse effects and toxicity","volume":"17","author":"Huestis","year":"2019","journal-title":"Curr. Neuropharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s40429-020-00326-8","article-title":"Therapeutic efficacy of cannabidiol (CBD): A review of the evidence from clinical trials and human laboratory studies","volume":"7","author":"Sholler","year":"2020","journal-title":"Curr. Addict. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","article-title":"Cannabidiol in patients with seizures associated with Lennox\u2013Gastaut syndrome (GWPCARE4): A randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Thiele","year":"2018","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","article-title":"Effect of cannabidiol on drop seizures in the Lennox\u2013Gastaut syndrome","volume":"378","author":"Devinsky","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/epi.14670","article-title":"Cannabidiol in patients with Lennox\u2013Gastaut syndrome: Interim analysis of an open-label extension study","volume":"60","author":"Thiele","year":"2019","journal-title":"Epilepsia"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e2220189","DOI":"10.1001\/jamanetworkopen.2022.20189","article-title":"Adjunctive transdermal cannabidiol for adults with focal epilepsy","volume":"5","author":"Berkovic","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"217","DOI":"10.5694\/mja18.00023","article-title":"Cannabidiol for treating drug-resistant epilepsy in children: The New South Wales experience","volume":"209","author":"Chen","year":"2018","journal-title":"Med. J. Aust."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1468-1331.2006.01639.x","article-title":"Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis","volume":"14","author":"Collin","year":"2007","journal-title":"Eur. J. Neurol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/00207454.2018.1481066","article-title":"Sativex\u00ae as add-on therapy vs. further optimized first-line antispastics (SAVANT) in resistant multiple sclerosis spasticity: A double-blind, placebo-controlled randomised clinical trial","volume":"129","author":"Essner","year":"2019","journal-title":"Int. J. Neurosci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"105740","DOI":"10.1016\/j.msard.2024.105740","article-title":"A randomized, double-blind, placebo-controlled trial to evaluate the effect of nabiximols oromucosal spray on clinical measures of spasticity in patients with multiple sclerosis","volume":"89","author":"Bethoux","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"17435","DOI":"10.1007\/s00210-025-04347-w","article-title":"A randomized trial on efficacy of purified cannabidiol on spasticity in multiple sclerosis patients with gait problems: First report in Iran","volume":"398","author":"Mousavi","year":"2025","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1017\/S1041610224000516","article-title":"Cannabidiol for behavioral symptoms in Alzheimer\u2019s disease (CANBiS-AD): A randomized, double-blind, placebo-controlled trial","volume":"36","author":"Velayudhan","year":"2024","journal-title":"Int. Psychogeriatr."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"afaf149","DOI":"10.1093\/ageing\/afaf149","article-title":"Sativex (nabiximols) for the treatment of agitation and aggression in Alzheimer\u2019s dementia in UK nursing homes: A randomised, double-blind, placebo-controlled feasibility trial","volume":"54","author":"Albertyn","year":"2025","journal-title":"Age Ageing"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Hermush, V., Ore, L., Stern, N., Mizrahi, N., Fried, M., Krivoshey, M., Staghon, E., Lederman, V.E., and Bar-Lev Schleider, L. (2022). Effects of rich cannabidiol oil on behavioral disturbances in patients with dementia: A placebo-controlled randomized clinical trial. Front. Med., 9.","DOI":"10.3389\/fmed.2022.951889"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"107841","DOI":"10.1016\/j.parkreldis.2025.107841","article-title":"Cannabidiol and cognitive functions\/inflammatory markers in Parkinson\u2019s disease: A double-blind randomized controlled trial at Buriram Hospital (CBD-PD-BRH trial)","volume":"135","author":"Mitarnun","year":"2025","journal-title":"Park. Relat. Disord."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/mds.29768","article-title":"Short-term cannabidiol with \u0394-9-Tetrahydrocannabinol in Parkinson\u2019s disease: A randomized trial","volume":"39","author":"Liu","year":"2024","journal-title":"Mov. Disord."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/0269881119895536","article-title":"Effects of acute cannabidiol administration on anxiety and tremors induced by a simulated public speaking test in patients with Parkinson\u2019s disease","volume":"34","author":"Tumas","year":"2020","journal-title":"J. Psychopharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.parkreldis.2021.01.001","article-title":"A single oral dose of cannabidiol did not reduce upper limb tremor in patients with essential tremor","volume":"83","author":"Crippa","year":"2021","journal-title":"Park. Relat. Disord."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1177\/0269881114550355","article-title":"Effects of cannabidiol in the treatment of patients with Parkinson\u2019s disease: An exploratory double-blind trial","volume":"28","author":"Chagas","year":"2014","journal-title":"J. Psychopharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"390","DOI":"10.2174\/1389201020666191202111534","article-title":"The effectiveness of topical cannabidiol oil in symptomatic relief of peripheral neuropathy of the lower extremities","volume":"21","author":"Xu","year":"2020","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1038\/s41591-025-03977-0","article-title":"Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: A phase 3 randomized placebo-controlled trial","volume":"31","author":"Karst","year":"2025","journal-title":"Nat. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/epi.12550","article-title":"ILAE official report: A practical clinical definition of epilepsy","volume":"55","author":"Fisher","year":"2014","journal-title":"Epilepsia"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1523\/JNEUROSCI.4465-07.2008","article-title":"Downregulation of the CB1 cannabinoid receptor and related molecular elements of the endocannabinoid system in epileptic human hippocampus","volume":"28","author":"Vajda","year":"2008","journal-title":"J. Neurosci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1528-1167.2010.02624.x","article-title":"Dynamic changes of CB1-receptor expression in hippocampi of epileptic mice and humans","volume":"51","author":"Nagy","year":"2010","journal-title":"Epilepsia"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mcn.2014.07.003","article-title":"Distinct modulation of the endocannabinoid system upon kainic acid-induced in vivo seizures and in vitro epileptiform bursting","volume":"62","author":"Fezza","year":"2014","journal-title":"Mol. Cell. Neurosci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1124\/jpet.103.051920","article-title":"The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy","volume":"307","author":"Wallace","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.1088208","article-title":"CB1 cannabinoid receptors and on-demand defense against excitotoxicity","volume":"302","author":"Marsicano","year":"2003","journal-title":"Science"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.celrep.2016.06.083","article-title":"Crucial roles of the endocannabinoid 2-arachidonoylglycerol in the suppression of epileptic seizures","volume":"16","author":"Sugaya","year":"2016","journal-title":"Cell Rep."},{"key":"ref_49","first-page":"309","article-title":"Epilepsy: Its symptoms, treatment, and relation to other chronic convulsive diseases","volume":"30","author":"Reynolds","year":"1862","journal-title":"Br. Foreign Medico-Chir. Rev."},{"key":"ref_50","unstructured":"(2025, September 03). Epilepsy and Other Chronic Convulsive Diseases: Their Causes, Symptoms and Treatment, Available online: https:\/\/collections.nlm.nih.gov\/catalog\/nlm:nlmuid-100954847-bk."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1528-1157.1979.tb04816.x","article-title":"The influence of cannabidiol and \u03949-tetrahydrocannabinol on cobalt epilepsy in rats","volume":"20","author":"Chiu","year":"1979","journal-title":"Epilepsia"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"105895","DOI":"10.1016\/j.nbd.2022.105895","article-title":"Cannabidiol inhibits microglia activation and mitigates neuronal damage induced by kainate in an in vitro seizure model","volume":"174","author":"Landucci","year":"2022","journal-title":"Neurobiol. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1111\/bph.14202","article-title":"Cannabidiol exerts antiepileptic effects by restoring hippocampal interneuron functions in a temporal lobe epilepsy model","volume":"175","author":"Khan","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1124\/jpet.109.159145","article-title":"Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo","volume":"332","author":"Jones","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Javadzadeh, Y., Santos, A., Aquilino, M.S., Mylvaganam, S., Urban, K., and Carlen, P.L. (2024). Cannabidiol exerts anticonvulsant effects alone and in combination with \u03949-THC through the 5-HT1A receptor in the neocortex of mice. Cells, 13.","DOI":"10.3390\/cells13060466"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Aguirre, C., M\u00e1rquez, L.A., Santiago-Casta\u00f1eda, C.L., Carmona-Cruz, F., Nu\u00f1ez-Lumbreras, M.d.l.A., Mart\u00ednez-Rojas, V.A., Alonso-Vanegas, M., Aguado-Carrillo, G., G\u00f3mez-V\u00edquez, N.L., and Galv\u00e1n, E.J. (2023). Cannabidiol modifies the glutamate over-release in brain tissue of patients and rats with epilepsy: A pilot study. Biomedicines, 11.","DOI":"10.3390\/biomedicines11123237"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Martinez-Rojas, V.A., M\u00e1rquez, L.A., Martinez-Aguirre, C., Sollozo-Dupont, I., L\u00f3pez Preza, F.I., Fuentes Mej\u00eda, M., Alonso, M., Rocha, L., and Galv\u00e1n, E.J. (2025). Cannabidiol reduces synaptic strength and neuronal firing in layer V pyramidal neurons of the human cortex with drug-resistant epilepsy. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1627465"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"105128","DOI":"10.1016\/j.phrs.2020.105128","article-title":"Cannabidiol inhibits febrile seizure by modulating AMPA receptor kinetics through its interaction with the N-terminal domain of GluA1\/GluA2","volume":"161","author":"Yu","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e202416315","DOI":"10.1002\/advs.202416315","article-title":"The DEC2\u2013SCN2A axis is essential for the anticonvulsant effects of cannabidiol by modulating neuronal plasticity","volume":"12","author":"Song","year":"2025","journal-title":"Adv. Sci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"eaat5979","DOI":"10.1126\/sciadv.aat5979","article-title":"The circadian dynamics of the hippocampal transcriptome and proteome is altered in experimental temporal lobe epilepsy","volume":"6","author":"Debski","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Massey, S., Quigley, A., Rochfort, S., Christodoulou, J., and Van Bergen, N.J. (2024). Cannabinoids and Genetic Epilepsy Models: A Review with Focus on CDKL5 Deficiency Disorder. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms251910768"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1080\/17460441.2024.2384455","article-title":"Innovative Drug Discovery Strategies in Epilepsy: Integrating Next-Generation Syndrome-Specific Mouse Models to Address Pharmacoresistance and Epileptogenesis","volume":"19","author":"Hawkins","year":"2024","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/epi.18177","article-title":"Cannabinoid-like Compounds Found in Non-Cannabis Plants Exhibit Antiseizure Activity in Genetic Mouse Models of Drug-Resistant Epilepsy","volume":"66","author":"Yip","year":"2025","journal-title":"Epilepsia"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"120072","DOI":"10.1016\/j.jep.2025.120072","article-title":"Cannabidiol Ameliorates Seizures and Neuronal Damage in Ferric Chloride-Induced Posttraumatic Epilepsy by Targeting TRPV1 Channel","volume":"351","author":"Ma","year":"2025","journal-title":"J. Ethnopharmacol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.yebeh.2017.04.001","article-title":"The Wistar Audiogenic Rat (WAR) Strain and Its Contributions to Epileptology and Related Comorbidities: History and Perspectives","volume":"71","author":"Umeoka","year":"2017","journal-title":"Epilepsy Behav."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Vitale, R.M., Iannotti, F.A., and Amodeo, P. (2021). The (Poly)Pharmacology of Cannabidiol in Neurological and Neuropsychiatric Disorders: Molecular Mechanisms and Targets. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094876"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.seizure.2012.03.001","article-title":"Cannabidiol Exerts Anti-Convulsant Effects in Animal Models of Temporal Lobe and Partial Seizures","volume":"21","author":"Jones","year":"2012","journal-title":"Seizure"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s12098-024-05337-1","article-title":"Update on Cannabidiol in Drug-Resistant Epilepsy","volume":"92","author":"Singh","year":"2025","journal-title":"Indian J. Pediatr."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s40263-025-01201-8","article-title":"Clinically Meaningful Reduction in Drop Seizures in Patients with Lennox\u2013Gastaut Syndrome Treated with Cannabidiol: Post Hoc Analysis of Phase 3 Clinical Trials","volume":"39","author":"Specchio","year":"2025","journal-title":"CNS Drugs"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e1204","DOI":"10.1212\/WNL.0000000000005254","article-title":"Randomized, Dose-Ranging Safety Trial of Cannabidiol in Dravet Syndrome","volume":"90","author":"Devinsky","year":"2018","journal-title":"Neurology"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"B\u00f6rnsen, L., Romme Christensen, J., Ratzer, R., Hedegaard, C., S\u00f8ndergaard, H.B., Krakauer, M., Hesse, D., Nielsen, C.H., Sorensen, P.S., and Sellebjerg, F. (2015). Endogenous Interferon-\u03b2-Inducible Gene Expression and Interferon-\u03b2 Treatment Are Associated with Reduced T Cell Responses to Myelin Basic Protein in Multiple Sclerosis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0118830"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Navarrete, C., Garc\u00eda-Mart\u00edn, A., Rolland, A., DeMesa, J., and Mu\u00f1oz, E. (2021). Cannabidiol and Other Cannabinoids in Demyelinating Diseases. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22062992"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Tomaszewska-Zaremba, D., Gajewska, A., and Misztal, T. (2025). Anti-Inflammatory Effects of Cannabinoids in Therapy of Neurodegenerative Disorders and Inflammatory Diseases of the CNS. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26146570"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s42238-024-00232-0","article-title":"Selected Cannabis Cultivars Modulate Glial Activation: In Vitro and In Vivo Studies","volume":"6","author":"Sharon","year":"2024","journal-title":"J. Cannabis Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12974-022-02540-9","article-title":"A Cannabidiol Aminoquinone Derivative Activates the PP2A\/B55\u03b1\/HIF Pathway and Shows Protective Effects in a Murine Model of Traumatic Brain Injury","volume":"19","author":"Navarrete","year":"2022","journal-title":"J. Neuroinflamm."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"788","DOI":"10.4103\/1673-5374.382220","article-title":"Cannabinoids and Endocannabinoids as Therapeutics for Nervous System Disorders: Preclinical Models and Clinical Studies","volume":"19","author":"Duncan","year":"2024","journal-title":"Neural Regen. Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s11481-021-09982-7","article-title":"Immunomodulatory Potential of Cannabidiol in Multiple Sclerosis: A Systematic Review","volume":"16","author":"Furgiuele","year":"2021","journal-title":"J. Neuroimmune Pharmacol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Jones, \u00c9., and Vlachou, S. (2020). A Critical Review of the Role of the Cannabinoid Compounds \u03949-Tetrahydrocannabinol (\u03949-THC) and Cannabidiol (CBD) and Their Combination in Multiple Sclerosis Treatment. Molecules, 25.","DOI":"10.3390\/molecules25214930"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Elliott, D.M., Singh, N., Nagarkatti, M., and Nagarkatti, P.S. (2018). Cannabidiol Attenuates Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis through Induction of Myeloid-Derived Suppressor Cells. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.01782"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.expneurol.2017.08.017","article-title":"Mechanisms of Action of Cannabidiol in Adoptively Transferred Experimental Autoimmune Encephalomyelitis","volume":"298","author":"Torres","year":"2017","journal-title":"Exp. Neurol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/j.1476-5381.2011.01379.x","article-title":"Cannabidiol Inhibits Pathogenic T Cells, Decreases Spinal Microglial Activation and Ameliorates Multiple Sclerosis-like Disease in C57BL\/6 Mice","volume":"163","author":"Kozela","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.neuroscience.2015.01.030","article-title":"Interaction between the Protective Effects of Cannabidiol and Palmitoylethanolamide in an Experimental Model of Multiple Sclerosis in C57BL\/6 Mice","volume":"290","author":"Rahimi","year":"2015","journal-title":"Neuroscience"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1007\/s12035-022-03170-1","article-title":"Autophagic Molecular Alterations in the Mouse Cerebellum Experimental Autoimmune Encephalomyelitis Model Following Treatment with Cannabidiol and Fluoxetine","volume":"60","author":"Soleimani","year":"2023","journal-title":"Mol. Neurobiol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1089\/can.2022.0103","article-title":"Cannabidiol Attenuates In Vivo Leukocyte Recruitment to the Spinal Cord Microvasculature at Peak Disease of Experimental Autoimmune Encephalomyelitis","volume":"9","author":"Bernardes","year":"2024","journal-title":"Cannabis Cannabinoid Res."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Al-Ghezi, Z.Z., Miranda, K., Nagarkatti, M., and Nagarkatti, P.S. (2019). Combination of Cannabinoids, \u03949-Tetrahydrocannabinol and Cannabidiol, Ameliorates Experimental Multiple Sclerosis by Suppressing Neuroinflammation through Regulation of miRNA-Mediated Signaling Pathways. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01921"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.bbi.2019.07.028","article-title":"Combination of Cannabinoids, Delta-9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD), Mitigates Experimental Autoimmune Encephalomyelitis (EAE) by Altering the Gut Microbiome","volume":"82","author":"Busbee","year":"2019","journal-title":"Brain Behav. Immun."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1517\/14656566.7.5.607","article-title":"Sativex\u00ae: Clinical Efficacy and Tolerability in the Treatment of Symptoms of Multiple Sclerosis and Neuropathic Pain","volume":"7","author":"Barnes","year":"2006","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1586\/ern.11.47","article-title":"THC and CBD Oromucosal Spray (Sativex\u00ae) in the Management of Spasticity Associated with Multiple Sclerosis","volume":"11","author":"Vila","year":"2011","journal-title":"Expert Rev. Neurother."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1586\/ern.11.27","article-title":"Sativex\u00ae (Tetrahydrocannabinol + Cannabidiol), an Endocannabinoid System Modulator: Basic Features and Main Clinical Data","volume":"11","author":"Vermersch","year":"2011","journal-title":"Expert Rev. Neurother."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"656582","DOI":"10.1155\/2015\/656582","article-title":"Sativex in the Management of Multiple Sclerosis-Related Spasticity: Role of the Corticospinal Modulation","volume":"2015","author":"Russo","year":"2015","journal-title":"Neural Plast."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/WNF.0b013e3181633497","article-title":"Psychopathological and Cognitive Effects of Therapeutic Cannabinoids in Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Crossover Study","volume":"32","author":"Aragona","year":"2009","journal-title":"Clin. Neuropharmacol."},{"key":"ref_92","first-page":"122","article-title":"A Multicentre, Double-Blind, Randomised, Parallel-Group, Placebo-Controlled Study of the Effect of Long-Term Sativex\u00ae Treatment on Cognition and Mood in Patients with Spasticity Due to Multiple Sclerosis","volume":"1","author":"Fiedler","year":"2013","journal-title":"J. Mult. Scler."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/hup.1196","article-title":"A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Subjective Abuse Potential and Cognitive Effects of Nabiximols Oromucosal Spray in Subjects with a History of Recreational Cannabis Use","volume":"26","author":"Schoedel","year":"2011","journal-title":"Hum. Psychopharmacol."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"D\u2019hooghe, M., Willekens, B., Delvaux, V., D\u2019haeseleer, M., Guillaume, D., Laureys, G., Nagels, G., Vanderdonckt, P., Van Pesch, V., and Popescu, V. (2021). Sativex\u00ae (Nabiximols) Cannabinoid Oromucosal Spray in Patients with Resistant Multiple Sclerosis Spasticity: The Belgian Experience. BMC Neurol., 21.","DOI":"10.1186\/s12883-021-02246-0"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/ern.12.12","article-title":"Evaluation of the Safety and Tolerability Profile of Sativex: Is It Reassuring Enough?","volume":"12","author":"Wade","year":"2012","journal-title":"Expert Rev. Neurother."},{"key":"ref_96","unstructured":"Medicines and Healthcare Products Regulatory Agency (2010). Sativex Oromucosal Spray, Public Assessment Report; UK\/H\/2462\/001\/DC."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1038\/s41386-025-02213-0","article-title":"Cannabidiol Prevents Cognitive and Social Deficits in a Male Rat Model of Alzheimer\u2019s Disease through CB1 Activation and Inflammation Modulation","volume":"50","author":"Toledano","year":"2025","journal-title":"Neuropsychopharmacology"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nrn3880","article-title":"Immune Attack: The Role of Inflammation in Alzheimer Disease","volume":"16","author":"Heppner","year":"2015","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0197-4580(00)00124-X","article-title":"Inflammation and Alzheimer\u2019s Disease","volume":"21","author":"Akiyama","year":"2000","journal-title":"Neurobiol. Aging"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12974-020-02054-2","article-title":"Comparisons of Neuroinflammation, Microglial Activation, and Degeneration of the Locus Coeruleus\u2013Norepinephrine System in APP\/PS1 and Aging Mice","volume":"18","author":"Cao","year":"2021","journal-title":"J. Neuroinflamm."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e70229","DOI":"10.1111\/ejn.70229","article-title":"Cannabidiol and Alzheimer Disease: A Comprehensive Review and In Silico Insights into Molecular Interactions","volume":"62","author":"Tureck","year":"2025","journal-title":"Eur. J. Neurosci."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"445","DOI":"10.31887\/DCNS.2013.15.4\/hjahn","article-title":"Memory Loss in Alzheimer\u2019s Disease","volume":"15","author":"Jahn","year":"2013","journal-title":"Dialogues Clin. Neurosci."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13195-025-01756-0","article-title":"Cannabidiol as a Multifaceted Therapeutic Agent: Mitigating Alzheimer\u2019s Disease Pathology and Enhancing Cognitive Function","volume":"17","author":"Lillo","year":"2025","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"105880","DOI":"10.1016\/j.tiv.2024.105880","article-title":"Cannabidiol Protects Mouse Hippocampal Neurons from Neurotoxicity Induced by Amyloid \u03b2-Peptide25\u201335","volume":"99","author":"Salgado","year":"2024","journal-title":"Toxicol. In Vitro"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.neulet.2006.01.047","article-title":"Cannabidiol Inhibits Inducible Nitric Oxide Synthase Protein Expression and Nitric Oxide Production in Beta-Amyloid-Stimulated PC12 Neurons through p38 MAP Kinase and NF-\u03baB Involvement","volume":"399","author":"Esposito","year":"2006","journal-title":"Neurosci. Lett."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Alali, S., Riazi, G., Ashrafi-Kooshk, M.R., Meknatkhah, S., Ahmadian, S., Hooshyari Ardakani, M., and Hosseinkhani, B. (2021). Cannabidiol Inhibits Tau Aggregation In Vitro. Cells, 10.","DOI":"10.3390\/cells10123521"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Coles, M., Watt, G., Kreilaus, F., and Karl, T. (2020). Medium-Dose Chronic Cannabidiol Treatment Reverses Object Recognition Memory Deficits of APPswe\/PS1\u0394E9 Transgenic Female Mice. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.587604"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1021\/acsbiomaterials.5c00465","article-title":"Engineered PLGA Nanoparticles for Brain-Targeted Codelivery of Cannabidiol and pApoE2 through the Intranasal Route for the Treatment of Alzheimer\u2019s Disease","volume":"11","author":"Mahanta","year":"2025","journal-title":"ACS Biomater. Sci. Eng."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1021\/acschemneuro.4c00392","article-title":"Mannose-Functionalized Chitosan-Coated PLGA Nanoparticles for Brain-Targeted Codelivery of CBD and BDNF for the Treatment of Alzheimer\u2019s Disease","volume":"15","author":"Mahanta","year":"2024","journal-title":"ACS Chem. Neurosci."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"de Paula Faria, D., Estessi de Souza, L., Duran, F.L.S., Buchpiguel, C.A., Britto, L.R., Crippa, J.A.S., Filho, G.B., and Real, C.C. (2022). Cannabidiol Treatment Improves Glucose Metabolism and Memory in a Streptozotocin-Induced Alzheimer\u2019s Disease Rat Model: A Proof-of-Concept Study. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031076"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Goodland, M.N., Banerjee, S., Niehoff, M.L., Young, B.J., Macarthur, H., Butler, A.A., Morley, J.E., and Farr, S.A. (2025). Cannabidiol Improves Learning and Memory Deficits and Alleviates Anxiety in 12-Month-Old SAMP8 Mice. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0296586"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/15287394.2024.2338914","article-title":"Cannabidiol Improves the Cognitive Function of SAMP8 Alzheimer\u2019s Disease Model Mice Involving the Microbiota\u2013Gut\u2013Brain Axis","volume":"87","author":"Ma","year":"2024","journal-title":"J. Toxicol. Environ. Health A"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"937","DOI":"10.3233\/JAD-191242","article-title":"Chronic Treatment with 50 mg\/kg Cannabidiol Improves Cognition and Moderately Reduces A\u03b240 Levels in 12-Month-Old Male A\u03b2PPswe\/PS1\u0394E9 Transgenic Mice","volume":"74","author":"Watt","year":"2020","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3233\/ADR-210294","article-title":"The Relationship between Anxiety and Alzheimer\u2019s Disease","volume":"5","author":"Mendez","year":"2021","journal-title":"J. Alzheimer\u2019s Dis. Rep."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"973","DOI":"10.3233\/JAD-210026","article-title":"Cannabidiol Ameliorates Cognitive Function via Regulation of IL-33 and TREM2 Upregulation in a Murine Model of Alzheimer\u2019s Disease","volume":"80","author":"Khodadadi","year":"2021","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Bishara, M.A., Chum, P.P., Miot, F.E.L., Hooda, A., Hartman, R.E., and Behringer, E.J. (2025). Molecular Pathogenesis of Alzheimer\u2019s Disease Onset in a Mouse Model: Effects of Cannabidiol Treatment. Front. Neurosci., 19.","DOI":"10.3389\/fnins.2025.1667585"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/ptr.5095","article-title":"Cannabidiol Promotes Amyloid Precursor Protein Ubiquitination and Reduction of Beta Amyloid Expression in SH-SY5YAPP+ Cells through PPAR\u03b3 Involvement","volume":"28","author":"Scuderi","year":"2014","journal-title":"Phytother. Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"834","DOI":"10.12775\/JEHS.2022.12.09.097","article-title":"Cannabidiol in the Treatment and Prevention of Alzheimer\u2019s Disease\u2014A Comprehensive Overview of In Vitro and In Vivo Studies","volume":"12","author":"Skrobas","year":"2022","journal-title":"J. Educ. Health Sport"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"977","DOI":"10.3233\/JAD-141014","article-title":"Cannabis-Based Medicine Reduces Multiple Pathological Processes in A\u03b2PP\/PS1 Mice","volume":"43","author":"Aso","year":"2015","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.3233\/JAD-140921","article-title":"Long-Term Cannabidiol Treatment Prevents the Development of Social Recognition Memory Deficits in Alzheimer\u2019s Disease Transgenic Mice","volume":"42","author":"Cheng","year":"2014","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"118624","DOI":"10.1016\/j.lfs.2020.118624","article-title":"Cannabidiol (CBD) Enhanced the Hippocampal Immune Response and Autophagy of APP\/PS1 Alzheimer\u2019s Mice Uncovered by RNA-Seq","volume":"264","author":"Hao","year":"2021","journal-title":"Life Sci."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1089\/can.2023.0101","article-title":"Effects of Chronic, Low-Dose Cannabinoids, Cannabidiol, Delta-9-Tetrahydrocannabinol and a Combination of Both, on Amyloid Pathology in the 5xFAD Mouse Model of Alzheimer\u2019s Disease","volume":"9","author":"Arnanz","year":"2024","journal-title":"Cannabis Cannabinoid Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e00439","DOI":"10.1016\/j.neurot.2024.e00439","article-title":"A Combination of \u03949-Tetrahydrocannabinol and Cannabidiol Modulates Glutamate Dynamics in the Hippocampus of an Animal Model of Alzheimer\u2019s Disease","volume":"21","author":"Adell","year":"2024","journal-title":"Neurotherapeutics"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"174101","DOI":"10.1016\/j.pbb.2025.174101","article-title":"Combination Treatment with Medium Dose THC and CBD Had No Therapeutic Effect in a Transgenic Mouse Model for Alzheimer\u2019s Disease but Affected Other Domains Including Anxiety-Related Behaviours and Object Recognition Memory","volume":"257","author":"Aumer","year":"2025","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s42238-024-00222-2","article-title":"A Narrative Review of the Therapeutic and Remedial Prospects of Cannabidiol with Emphasis on Neurological and Neuropsychiatric Disorders","volume":"6","author":"Omotayo","year":"2024","journal-title":"J. Cannabis Res."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"334","DOI":"10.2174\/1871527319666200708130745","article-title":"Impact of Cannabis-Based Medicine on Alzheimer\u2019s Disease by Focusing on the Amyloid \u03b2-Modifications: A Systematic Study","volume":"19","author":"Farkhondeh","year":"2020","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1177\/0706743719892717","article-title":"Cannabinoids for the Neuropsychiatric Symptoms of Dementia: A Systematic Review and Meta-Analysis","volume":"65","author":"Bahji","year":"2020","journal-title":"Can. J. Psychiatry"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1055\/a-2262-7837","article-title":"Cannabinoids for Behavioral Symptoms in Dementia: An Overview","volume":"57","author":"Broers","year":"2024","journal-title":"Pharmacopsychiatry"},{"key":"ref_129","first-page":"799","article-title":"Neuropsychiatric Symptoms in Dementia. The Added Value of Cannabinoids. Are They a Safe and Effective Choice? Case Series with Cannabidiol 3%","volume":"7","author":"Papadopoulou","year":"2022","journal-title":"Ann. Case Rep."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1080\/07317115.2023.2209563","article-title":"The Effect of Cannabidiol 3% on Neuropsychiatric Symptoms in Dementia\u2014Six-Month Follow-Up","volume":"47","author":"Alexandri","year":"2024","journal-title":"Clin. Gerontol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000541364","article-title":"Treatment of Neuropsychiatric Symptoms in Alzheimer\u2019s Disease with a Cannabis-Based Magistral Formulation: An Open-Label Prospective Cohort Study","volume":"7","author":"Navarro","year":"2024","journal-title":"Med. Cannabis Cannabinoids"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1089\/can.2023.0023","article-title":"Cannabinoids in Treating Parkinson\u2019s Disease Symptoms: A Systematic Review of Clinical Studies","volume":"8","author":"Varshney","year":"2023","journal-title":"Cannabis Cannabinoid Res."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"e160499","DOI":"10.5812\/ijpr-160499","article-title":"Cannabidiol Extracted from Cannabis sativa L. Shows Neuroprotective Impacts Against 6-OHDA-Induced Neurotoxicity via Nrf2 Signal Transduction Pathway","volume":"24","author":"Esfandi","year":"2025","journal-title":"Iran. J. Pharm. Res."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Giuliano, C., Francavilla, M., Ongari, G., Petese, A., Ghezzi, C., Rossini, N., Blandini, F., and Cerri, S. (2021). Neuroprotective and Symptomatic Effects of Cannabidiol in an Animal Model of Parkinson\u2019s Disease. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22168920"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"107808","DOI":"10.1016\/j.neuropharm.2019.107808","article-title":"Cannabidiol Increases the Nociceptive Threshold in a Preclinical Model of Parkinson\u2019s Disease","volume":"163","author":"Ferrari","year":"2020","journal-title":"Neuropharmacology"},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Lima, A.C., Bioni, V.S., Becegato, M.S., Meier, Y., Cunha, D.M.G., Aguiar, N.A., Gon\u00e7alves, N., Peres, F.F., Zuardi, A.W., and Hallak, J.E.C. (2025). Preventive Beneficial Effects of Cannabidiol in a Reserpine-Induced Progressive Model of Parkinsonism. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1539783"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"177748","DOI":"10.1016\/j.ejphar.2025.177748","article-title":"Neuroprotective Effects of a Cannabidiol Nanoemulsion in a Rotenone-Induced Rat Model of Parkinson\u2019s Disease: Insights into the Gut\u2013Brain Axis","volume":"1002","author":"Santos","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"111456","DOI":"10.1016\/j.pnpbp.2025.111456","article-title":"Cannabidiol Improves L-DOPA-Induced Dyskinesia and Modulates Neuroinflammation and the Endocannabinoid, Endovanilloid and Nitrergic Systems","volume":"141","author":"Nascimento","year":"2025","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Lapmanee, S., Bhubhanil, S., Wongchitrat, P., Charoenphon, N., Inchan, A., Ngernsutivorakul, T., Dechbumroong, P., Khongkow, M., and Namdee, K. (2024). Assessing the Safety and Therapeutic Efficacy of Cannabidiol Lipid Nanoparticles in Alleviating Metabolic and Memory Impairments and Hippocampal Histopathological Changes in Diabetic Parkinson\u2019s Rats. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16040514"},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Belardo, C., Iannotta, M., Boccella, S., Rubino, R.C., Ricciardi, F., Infantino, R., Pieretti, G., Stella, L., Paino, S., and Marabese, I. (2019). Oral Cannabidiol Prevents Allodynia and Neurological Dysfunctions in a Mouse Model of Mild Traumatic Brain Injury. Front. Pharmacol., 10.","DOI":"10.3389\/fphar.2019.00352"},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Meyer, E., Rieder, P., Gobbo, D., Candido, G., Scheller, A., de Oliveira, R.M.W., and Kirchhoff, F. (2022). Cannabidiol Exerts a Neuroprotective and Glia-Balancing Effect in the Subacute Phase of Stroke. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232112886"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41401-022-01004-3","article-title":"Mitofusin-2 Mediates Cannabidiol-Induced Neuroprotection against Cerebral Ischemia in Rats","volume":"44","author":"Xu","year":"2023","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"114654","DOI":"10.1016\/j.expneurol.2023.114654","article-title":"Involvement of CKS1B in the Anti-Inflammatory Effects of Cannabidiol in Experimental Stroke Models","volume":"373","author":"Chen","year":"2024","journal-title":"Exp. Neurol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"e2009","DOI":"10.1089\/neu.2023.0539","article-title":"Cannabidiol Alleviates Neurological Deficits after Traumatic Brain Injury by Improving Intracranial Lymphatic Drainage","volume":"41","author":"Dong","year":"2024","journal-title":"J. Neurotrauma"},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Santiago-Casta\u00f1eda, C., Huerta de la Cruz, S., Mart\u00ednez-Aguirre, C., Orozco-Su\u00e1rez, S.A., and Rocha, L. (2022). Cannabidiol Reduces Short- and Long-Term High Glutamate Release after Severe Traumatic Brain Injury and Improves Functional Recovery. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14081609"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"114076","DOI":"10.1016\/j.bbr.2022.114076","article-title":"Cannabidiol Enhances the Antinociceptive Effects of Morphine and Attenuates Opioid-Induced Tolerance in the Chronic Constriction Injury Model","volume":"435","author":"Jesus","year":"2022","journal-title":"Behav. Brain Res."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/s41386-019-0585-3","article-title":"Orally Consumed Cannabinoids Provide Long-Lasting Relief of Allodynia in a Mouse Model of Chronic Neuropathic Pain","volume":"45","author":"Abraham","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Sepulveda, D.E., Vrana, K.E., Graziane, N.M., and Raup-Konsavage, W.M. (2022). Combinations of Cannabidiol and \u03949-Tetrahydrocannabinol in Reducing Chemotherapeutic-Induced Neuropathic Pain. Biomedicines, 10.","DOI":"10.3390\/biomedicines10102548"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"108529","DOI":"10.1016\/j.neuropharm.2021.108529","article-title":"Oral Efficacy of \u03949-Tetrahydrocannabinol and Cannabidiol in a Mouse Neuropathic Pain Model","volume":"189","author":"Mitchell","year":"2021","journal-title":"Neuropharmacology"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1111\/bph.15486","article-title":"Behavioural and Pharmacological Effects of Cannabidiol (CBD) and the Cannabidiol Analogue KLS-13019 in Mouse Models of Pain and Reinforcement","volume":"178","author":"Foss","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/jpp\/rgad023","article-title":"Cannabidiol Prevents Chemotherapy-Induced Neuropathic Pain by Modulating Spinal TLR4 via Endocannabinoid System Activation","volume":"75","author":"Veras","year":"2023","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"110265","DOI":"10.1016\/j.neuropharm.2024.110265","article-title":"Acute Kappa Opioid Receptor Blocking Disrupts the Pro-Cognitive Effect of Cannabidiol in Neuropathic Rats","volume":"266","author":"Boccella","year":"2025","journal-title":"Neuropharmacology"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.jhsa.2024.09.015","article-title":"The Use of Cannabinoids in the Treatment of Peripheral Neuropathy and Neuropathic Pain: A Systematic Review","volume":"50","author":"Choi","year":"2025","journal-title":"J. Hand Surg."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1097\/j.pain.0000000000002466","article-title":"Cannabidiol Treatment in Hand Osteoarthritis and Psoriatic Arthritis: A Randomized, Double-Blind, Placebo-Controlled Trial","volume":"163","author":"Vela","year":"2022","journal-title":"Pain"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/ejp.2072","article-title":"Oral Capsules of Tetra-Hydro-Cannabinol (THC), Cannabidiol (CBD) and Their Combination in Peripheral Neuropathic Pain Treatment","volume":"27","author":"Zubcevic","year":"2023","journal-title":"Eur. J. Pain"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1002\/jnr.22682","article-title":"Neuroprotective Effects of Phytocannabinoid-Based Medicines in Experimental Models of Huntington\u2019s Disease","volume":"89","author":"Sagredo","year":"2011","journal-title":"J. Neurosci. Res."},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Valdeolivas, S., Sagredo, O., Delgado, M., Pozo, M.A., and Fern\u00e1ndez-Ruiz, J. (2017). Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6\/2 Mice, an Experimental Model of Huntington\u2019s Disease. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18040684"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/0091-3057(91)90386-G","article-title":"Controlled Clinical Trial of Cannabidiol in Huntington\u2019s Disease","volume":"40","author":"Consroe","year":"1991","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/bs.pmbts.2019.06.005","article-title":"Effects of Cannabidiol (CBD) in Neuropsychiatric Disorders: A Review of Pre-Clinical and Clinical Findings","volume":"Volume 167","author":"Elsaid","year":"2019","journal-title":"Progress in Molecular Biology and Translational Science"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1007\/s00415-016-8145-9","article-title":"A Double-Blind, Randomized, Cross-Over, Placebo-Controlled, Pilot Trial with Sativex in Huntington\u2019s Disease","volume":"263","author":"Sagredo","year":"2016","journal-title":"J. Neurol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1200\/JCO.22.01632","article-title":"Phase IIb Randomized, Placebo-Controlled, Dose-Escalating, Double-Blind Study of Cannabidiol Oil for the Relief of Symptoms in Advanced Cancer (MedCan1-CBD)","volume":"41","author":"Hardy","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_162","first-page":"715","article-title":"Medicinal Cannabis for Symptom Control in Advanced Cancer: A Double-Blind, Placebo-Controlled, Randomised Clinical Trial of 1:1 Tetrahydrocannabinol and Cannabidiol","volume":"33","author":"Hardy","year":"2025","journal-title":"Support. Care Cancer"},{"key":"ref_163","first-page":"631","article-title":"Oral Cannabis for Taxane-Induced Neuropathy: A Pilot Randomized Placebo-Controlled Study","volume":"10","author":"Haney","year":"2025","journal-title":"Cannabis Cannabinoid Res."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s42238-025-00366-9","article-title":"Placebo Effects in a RCT Assessing 30 Days of Low Dose Cannabidiol (CBD) Treatment for Psychological Distress in Stressed Students at Risk for Depression","volume":"7","author":"Winkler","year":"2025","journal-title":"J. Cannabis Res."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1177\/02698811231219060","article-title":"The Impact of Cannabidiol Placebo on Responses to an Acute Stressor: A Replication and Proof-of-Concept Study","volume":"38","author":"Zhekova","year":"2024","journal-title":"J. Psychopharmacol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000528528","article-title":"CANNabinoid Drug Interaction Review (CANN-DIRTM)","volume":"6","author":"Kocis","year":"2023","journal-title":"Med. Cannabis Cannabinoids"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"e13812","DOI":"10.1111\/cts.13812","article-title":"Evaluation of Potential Drug\u2013Drug Interactions with Medical Cannabis","volume":"17","author":"Ho","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1055\/a-2593-6351","article-title":"Evidence of Potential Drug Interactions Between Cannabidiol and Other Drugs: A Scoping Review to Guide Pharmaceutical Care","volume":"91","author":"Nader","year":"2025","journal-title":"Planta Med."},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"International Transporter Consortium, Giacomini, K.M., Huang, S.-M., Tweedie, D.J., Benet, L.Z., Brouwer, K.L.R., Chu, X., Dahlin, A., Evers, R., and Fischer, V. (2010). Membrane Transporters in Drug Development. Nat. Rev. Drug Discov., 9, 215\u2013236.","DOI":"10.1038\/nrd3028"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1124\/jpet.105.098541","article-title":"Characterization of P-Glycoprotein Inhibition by Major Cannabinoids from Marijuana","volume":"317","author":"Zhu","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00213-006-0437-9","article-title":"Evaluation of Antipsychotic Drugs as Inhibitors of Multidrug Resistance Transporter P-Glycoprotein","volume":"187","author":"Wang","year":"2006","journal-title":"Psychopharmacology"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/epi.13060","article-title":"Drug\u2013Drug Interaction Between Clobazam and Cannabidiol in Children with Refractory Epilepsy","volume":"56","author":"Geffrey","year":"2015","journal-title":"Epilepsia"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1007\/s11606-020-06504-8","article-title":"Cannabidiol Interactions with Medications, Illicit Substances, and Alcohol: A Comprehensive Review","volume":"36","author":"Balachandran","year":"2021","journal-title":"J. Gen. Intern. Med."},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Coates, S., Bardhi, K., Prasad, B., and Lazarus, P. (2024). Evaluation of the Drug\u2013Drug Interaction Potential of Cannabidiol Against UGT2B7-Mediated Morphine Metabolism Using Physiologically Based Pharmacokinetic Modeling. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16121599"},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Campos, M.G., China, M., Cl\u00e1udio, M., Capinha, M., Torres, R., Oliveira, S., and Fortuna, A. (2024). Drug\u2013Cannabinoid Interactions in Selected Therapeutics for Symptoms Associated with Epilepsy, Autism Spectrum Disorder, Cancer, Multiple Sclerosis, and Pain. Pharmaceuticals, 17.","DOI":"10.3390\/ph17050613"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"e70455","DOI":"10.1111\/cts.70455","article-title":"Genotype\u2013Specific Safety and Pharmacokinetics of Cannabidiol in Healthy Volunteers","volume":"19","author":"Etkins","year":"2025","journal-title":"Clin. Transl. Sci."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/2\/330\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T05:35:25Z","timestamp":1772084125000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/2\/330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":176,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["ph19020330"],"URL":"https:\/\/doi.org\/10.3390\/ph19020330","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]}}}